<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01848028</url>
  </required_header>
  <id_info>
    <org_study_id>IVDP-085-07</org_study_id>
    <nct_id>NCT01848028</nct_id>
  </id_info>
  <brief_title>PsoBest - The German Psoriasis Registry</brief_title>
  <official_title>Long-Term Benefits and Safety of Systemic Psoriasis Therapy: German Registry on the Treatment of Psoriasis With Biologics and Systemic Therapeutics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitätsklinikum Hamburg-Eppendorf</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Berufsverband der Deutschen Dermatologen e.V. (BVDD)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Deutsche Dermatologische Gesellschaft e.V. (DDG)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>AbbVie</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Janssen-Cilag G.m.b.H</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>medac GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer Deutschland GmbH</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Serono GmbH (former collaborator)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>PsoNet.eu</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitätsklinikum Hamburg-Eppendorf</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment of moderate to severe Psoriasis (Pso) and Psoriasis-Arthritis (PsA) is largely
      confined to systemic therapy in Germany. Systemic therapy includes conventional systemic
      therapy (e.g. fumaric acids, methotrexate, ciclosporin A) and biological treatment (e.g.
      adalimumab, etanercept). While short- and middle-term efficacy of most systemic treatments
      has been shown in clinical studies (and is incorporated in international guidelines),
      knowledge about long-term outcomes, optimal treatment and effectiveness under real-world
      conditions is still missing. PsoBest, the German registry on the treatment of moderate to
      severe Pso and PsA started in 2008 and documents the long-term course of patients being
      administered any biologic or conventional systemic antipsoriatic drug authorized in Germany
      for the first time. The registry evaluates the long-term course of 3,500 patients with Pso
      and PsA treated with systemic antipsoriatics.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Treatment of moderate to severe Psoriasis (Pso) and Psoriasis-Arthritis (PsA) is
      largely confined to systemic therapy in Germany. Systemic therapy includes conventional
      systemic therapy (e.g. fumaric acids, methotrexate, ciclosporin A) and biological treatment
      (e.g. adalimumab, etanercept). While short- and middle-term efficacy of most systemic
      treatments has been shown in clinical studies (and is incorporated in international
      guidelines), knowledge about long-term outcomes, optimal treatment and effectiveness under
      real-world conditions is still missing. PsoBest, the German registry on the treatment of
      moderate to severe Pso and PsA started in 2008 and documents the long-term course of patients
      being administered any biologic or conventional systemic antipsoriatic drug authorized in
      Germany for the first time.

      Objectives: Observation and analysis of the following outcomes of treatment with systemic
      antipsoriatics:

        1. Effectiveness in clinical practice (&quot;real world&quot;)

        2. Benefits and needs on the patients' side

        3. Effectiveness in a long-term course over years

        4. Optimal maintenance dosages

        5. Safety and side-effects profile under routine conditions

        6. Use in case of and effect on co-morbidity

        7. Reliable predictors of response

        8. Benefit and effectiveness of possible combination therapies or alternating use of
           biologics and systemic therapies

      Methods: The registry evaluates the long-term course of 3,500 patients with Pso and PsA
      treated with systemic antipsoriatics.The registry started for seven treatment arms: Fumaric
      acid, methotrexate, ciclosporin A, efalizumab, etanercept, infliximab and adalimumab. While
      efalizumab was withdrawn from the market, ustekinumab was included after authorization.
      Patients are included at first initiation of a given treatment and will remain in the
      registry for 5 years, regardless of subsequent therapy. Nationwide, dermatologic practices
      and hospital ambulances with expertise in systemic and biologic treatment consecutively enrol
      patients. Follow-ups will be every 3 to 6 months, comprising patient and treatment
      characteristics, clinical parameters, patient-defined benefit, quality of life and adverse
      events. Standardized questionnaires will be addressed to the patient and to the dermatologist
      12 times at the dermatologic centres. In interim intervals, patients are directly contacted
      another 9 times by mail. PsoBest is member of the ENCePP network of psoriasis-registries
      (www.psonet.eu).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>January 2008</start_date>
  <completion_date type="Anticipated">July 2026</completion_date>
  <primary_completion_date type="Anticipated">December 2025</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>10 Years</target_duration>
  <primary_outcome>
    <measure>Psoriasis Area Severity Index (PASI)</measure>
    <time_frame>every 6 month for 10 years</time_frame>
    <description>To evaluate clinical outcome of patients exposed to conventional systemic or biologic therapy for psoriasis/psoriatic-arthritis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Dermatology Life Quality Index (DLQI)</measure>
    <time_frame>every 3 month for 10 years</time_frame>
    <description>To evaluate disease related quality of life of patients exposed to conventional systemic or biologic therapy for psoriasis/psoriatic-arthritis</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse and serious adverse events</measure>
    <time_frame>6 month</time_frame>
    <description>Risk for adverse events and serious adverse events for patients exposed to conventional systemic or biologic therapy for psoriasis/psoriatic-arthritis</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient Benefit Index (PBI)</measure>
    <time_frame>every 3 months for 10 years</time_frame>
    <description>To evaluate the patient benefit of conventional systemic or biologic therapy for psoriasis/psoriatic-arthritis</description>
  </other_outcome>
  <other_outcome>
    <measure>EuroQol Questionnaire (EQ-5D)</measure>
    <time_frame>every 3 months for 10 years</time_frame>
    <description>To evaluate general state of health of patients exposed to conventional systemic or biologic therapy for psoriasis/psoriatic-arthritis</description>
  </other_outcome>
  <other_outcome>
    <measure>Questionnaire on Supply Quality in Dermatology (FVQ-d)</measure>
    <time_frame>every 3 months for 10 years</time_frame>
    <description>To evaluate care characteristics of conventional systemic or biologic therapy for psoriasis/psoriatic-arthritis</description>
  </other_outcome>
  <other_outcome>
    <measure>Health Assessment Questionnaire (HAQ)</measure>
    <time_frame>every 6 months for 10 years</time_frame>
    <description>To evaluate arthritis severity of patients exposed to conventional systemic or biologic therapy for psoriasis/psoriatic-arthritis</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient Global Assessment (Skin: PaGAs, Arthritis: PaGAa)</measure>
    <time_frame>every 3 months for 10 years</time_frame>
    <description>To evaluate global severity of skin and arthritis in patients exposed to conventional systemic or biologic therapy for psoriasis/psoriatic-arthritis</description>
  </other_outcome>
  <other_outcome>
    <measure>Physician Global Assessment (Skin: PGAs, Arthritis: PGAa)</measure>
    <time_frame>every 6 months for 10 years</time_frame>
    <description>To evaluate global severity of skin and arthritis in patients exposed to conventional systemic or biologic therapy for psoriasis/psoriatic-arthritis</description>
  </other_outcome>
  <other_outcome>
    <measure>Disease Activity Score 28 (DAS 28), American College of Rheumatology Score (ACR20), Psoriatic Arthritic Response Criteria (PsARC)</measure>
    <time_frame>every 6 months for 10 years</time_frame>
    <description>To evaluate arthritis severity of patients exposed to conventional systemic or biologic therapy for psoriasis/psoriatic-arthritis</description>
  </other_outcome>
  <number_of_groups>15</number_of_groups>
  <enrollment type="Anticipated">3500</enrollment>
  <condition>Psoriasis</condition>
  <condition>Psoriatic-arthritis</condition>
  <arm_group>
    <arm_group_label>Fumaric acid ester</arm_group_label>
    <description>Intervention: Drug: conventional systemic: Fumaric acid ester, all dosages, frequencies and durations prescribed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Methotrexate</arm_group_label>
    <description>Intervention: Drug: conventional systemic: Methotrexate, all dosages, frequencies and durations prescribed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cyclosporine A</arm_group_label>
    <description>Intervention: Drug: conventional systemic: Cyclosporine A, all dosages, frequencies and durations prescribed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Efalizumab (withdrawn)</arm_group_label>
    <description>Intervention: Biological: Efalizumab, all dosages, frequencies and durations prescribed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Etanercept</arm_group_label>
    <description>Intervention: Biological: Etanercept, all dosages, frequencies and durations prescribed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Infliximab</arm_group_label>
    <description>Intervention: Biological: Infliximab, all dosages, frequencies and durations prescribed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Adalimumab</arm_group_label>
    <description>Intervention: Biological: Adalimumab, all dosages, frequencies and durations prescribed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ustekinumab</arm_group_label>
    <description>Intervention: Biological: Ustekinumab, all dosages, frequencies and durations prescribed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Golimumab</arm_group_label>
    <description>Intervention: Biological: Golimumab, all dosages, frequencies and durations prescribed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Secukinumab</arm_group_label>
    <description>Intervention: Biological: Secukinumab, all dosages, frequencies and durations prescribed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Apremilast</arm_group_label>
    <description>Intervention: Small molecule: Apremilast, all dosages, frequencies and durations prescribed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Certolizumab</arm_group_label>
    <description>Intervention: Biological: Certolizumab, all dosages, frequencies and durations prescribed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Retinoids</arm_group_label>
    <description>Intervention: Drug: conventional systemic: Retinoids, all dosages, frequencies and durations prescribed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Leflunomids</arm_group_label>
    <description>Intervention: Drug: conventional systemic: Leflunomids, all dosages, frequencies and durations prescribed</description>
  </arm_group>
  <arm_group>
    <arm_group_label>systemic PUVA</arm_group_label>
    <description>Intervention: Drug: conventional systemic: systemic PUVA, all dosages, frequencies and durations prescribed</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with plaque-type psoriasis or psoriatic-arthritis starting the first systemic
        treatment with authorized atipsoriatic drugs in Germany.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with diagnosis of plaque-type psoriasis or psoriasis arthritis confirmed by a
             dermatologist

          -  age ≥ 18 years

          -  being administered a specific systemic drug for the first time

          -  informed consent to participate

          -  sufficient language skills (German)

        Exclusion criteria:

          -  lack of informed consent

          -  patients being participants of clinical trials at the day of admission to the registry
             (if a patient is included into a clinical trial during the registry follow-ups, the
             patient data will be recorded, but analysed separately)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Matthias Augustin, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitätsklinikum Hamburg-Eppendorf</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Nationwide group of dermatological centers, hospitals and medical offices</name>
      <address>
        <city>Hamburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Augustin, Prof. Dr.</last_name>
      <email>m.augustin@uke.de</email>
    </contact>
    <investigator>
      <last_name>Matthias Augustin, Prof. Dr.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <link>
    <url>http://www.psobest.de/</url>
    <description>PsoBest - the German psoriasis registry</description>
  </link>
  <link>
    <url>http://www.cvderm.de</url>
    <description>German Center for Health Services Research in Dermatology</description>
  </link>
  <link>
    <url>http://www.psonet.eu</url>
    <description>PsoNet - the European registry of psoriasis</description>
  </link>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 7, 2013</study_first_submitted>
  <study_first_submitted_qc>May 2, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 7, 2013</study_first_posted>
  <last_update_submitted>October 25, 2017</last_update_submitted>
  <last_update_submitted_qc>October 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 27, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Patient registry</keyword>
  <keyword>Germany</keyword>
  <keyword>Psoriasis</keyword>
  <keyword>psoriatic-arthritis</keyword>
  <keyword>Efalizumab</keyword>
  <keyword>Psonet</keyword>
  <keyword>Effectiveness</keyword>
  <keyword>Safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Psoriasis</mesh_term>
    <mesh_term>Arthritis, Psoriatic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ustekinumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

